Basel Medical Group Ltd confirmed that Nasdaq has determined the company has complied with the periodic filing requirement under Listing Rule 5250(c)(1). The determination followed the company’s amended Form 20‑F for fiscal year 2025, which was filed with the SEC on March 13 2026, and removes a potential delisting risk.
The company had previously received a Nasdaq notification for a filing deficiency. The amended report addressed the issues, and Basel Medical confirms it met all filing obligations for the year ended June 30 2025. This is the first public confirmation that Basel Medical satisfies Nasdaq’s listing requirements for the current reporting period.
While the compliance news is a positive development, Basel Medical’s financial performance remains challenging. For FY 2025 the company reported a net loss of 21.27 million SGD, compared with a 4.15 million SGD profit in FY 2024. Revenue was 11.32 million SGD, a slight decline from prior year levels, and the company posted a negative operating margin of 19.47 % and a net margin of 109.09 %. An Altman Z‑Score of –1.03 and a Beneish M‑Score of –1.28 signal financial distress, and the debt‑to‑equity ratio of 27.8 % indicates a leveraged balance sheet, although cash exceeds debt.
Basel Medical also faces a separate Nasdaq compliance issue: a notification for non‑compliance with the minimum bid price requirement of $1 per share. The company has until July 21 2026 to maintain a closing bid price of at least $1 for ten consecutive business days. The dual compliance matters underscore the company’s ongoing need to strengthen its financial position and market presence.
In addition to regulatory matters, Basel Medical completed the acquisition of Bethesda Medical for $6.5 million on April 30 2025, expanding its service footprint in Singapore. The company’s IPO on February 25 2025 raised $10.14 million at $4.00 per share, and it now operates seven clinics serving corporate clients in construction, marine, and oil and gas sectors.
The announcement was well received by investors, reflecting relief that the company has met Nasdaq’s filing requirements. However, the underlying financial challenges and the pending bid‑price compliance issue suggest that Basel Medical must continue to focus on improving profitability and liquidity to secure its long‑term listing status.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.